Penumbra, Inc. $PEN Shares Sold by Exome Asset Management LLC

Exome Asset Management LLC cut its holdings in Penumbra, Inc. (NYSE:PEN) by 30.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 6,300 shares of the company’s stock after selling 2,700 shares during the quarter. Exome Asset Management LLC’s holdings in Penumbra were worth $2,069,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Penumbra by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock valued at $238,365,000 after acquiring an additional 18,738 shares in the last quarter. Invesco Ltd. boosted its stake in Penumbra by 1.1% in the 4th quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock worth $198,455,000 after purchasing an additional 7,211 shares in the last quarter. Artisan Partners Limited Partnership grew its position in Penumbra by 165.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock worth $184,715,000 after purchasing an additional 370,636 shares during the last quarter. Janus Henderson Group PLC grew its position in Penumbra by 1.5% during the 4th quarter. Janus Henderson Group PLC now owns 475,898 shares of the company’s stock worth $147,962,000 after purchasing an additional 7,050 shares during the last quarter. Finally, Whitebox Advisors LLC purchased a new stake in Penumbra during the 1st quarter worth approximately $146,125,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Stock Performance

PEN opened at $319.46 on Tuesday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $12.56 billion, a PE ratio of 73.61, a P/E/G ratio of 1.98 and a beta of 0.70. The firm has a 50 day moving average of $319.32 and a two-hundred day moving average of $330.05.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The business’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.83 earnings per share. On average, analysts anticipate that Penumbra, Inc. will post 5.02 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PEN. Citigroup decreased their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada reissued a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a report on Thursday, June 11th. Wall Street Zen raised Penumbra to a “hold” rating in a research report on Saturday, May 9th. Evercore restated an “outperform” rating and issued a $320.00 target price on shares of Penumbra in a research note on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Penumbra has a consensus rating of “Hold” and a consensus target price of $360.33.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.